Full Press Release Details
Pharmaceuticals and sanofi-aventis Enter into an Agreement for the Insulin
supply of Oramed's Oral Insulin Capsules.
Israel, July 7, 2010- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of oral delivery systems, today announced
that Oramed entered into a Manufacturing Supply Agreement (MSA) with
sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with
specified quantities of recombinant human insulin to be used by Oramed for its
clinical trials in the USA.
is managed by the Commercial and External Partnership within Industrial Affairs
(CEPiA) at sanofi-aventis, which will allow Oramed to leverage sanofi-aventis'
ability and expertise regarding quality and regulatory support.
oral delivery technology together with sanofi-aventis capabilities to produce
insulin on a large scale supports Oramed's efforts to conduct clinical
development of Oramed's oral insulin capsule in the growing diabetes market in
the US.", says Nadav Kidron, Oramed's CEO. "It is very satisfying to work with
such a professional company and their dedicated staff."
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.